Neumentum is developing and plans to commercialize products that effectively treat pain, without the risks of abuse, misuse, diversion and side effects that may be found with opioids.
Neumentum’s product candidates include:
NTM-001 (pre-mixed bag ketorolac continuous infusion) has the potential to maintain pain relief at an opioid level, reducing or eliminating the need for opioids.
NTM-001 is a Phase 3-ready IV formulation of Toradol (ketorolac) for continuous infusion over 24 hours that is on track to receive FDA approval in 2021.
Earlier stage products include a novel intrathecal preparation of ketorolac and two novel non-opioid analgesic compounds that work similarly to acetaminophen (APAP), with the potential to be more potent and without the liver toxicity associated with APAP. Liver toxicity can be life-threatening and APAP overdose is the leading cause of acute liver failure in the US. Still, APAP is an active ingredient in over 600 prescribed and over-the-counter products, including Percocet, Vicodin, Tylenol and Excedrin. Our products have the potential to replace acetaminophen products in the prescription and OTC markets, with increased potency and without the risk of adverse effects like liver failure.
Our Product Candidates
-  Larson AM, et al. Hepatology, 2005 Dec; 42(6):1364-72